Lacking A Clear Disease Setting, Sanofi’s Semuloparin Fails ODAC Vote
Executive Summary
It isn’t clear to either FDA or the Oncologic Drugs Advisory Committee what specific cancer chemotherapy setting would be the most useful for Sanofi-Aventis’ semuloparin, a low molecular weight heparin intended to prevent venous thromboembolism.
You may also be interested in...
Sanofi-Aventis’ Semuloparin May Have Safety Advantage For ODAC To Consider
Unlike Pfizer and Eisai’s Fragmin (dalteparin), the new ultra-low-molecular-weight heparin does not appear to carry a hematoma risk.
Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says
Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.
Ranbaxy’s Atorvastatin Recall: Will Glass Shards Nick FDA’s Reputation?
Less than a year after signing a consent decree to resolve compliance problems, the company is forced to stop manufacturing its generic version of the best-selling cholesterol drug. For FDA, the issue poses a public relations challenge since it touches on several areas where the agency has recently been criticized – generic drug quality, manufacturing oversight and drug shortages.